F. Binder-foucard, Cancer incidence and mortality in France over the 1980-2012 period: Solid tumors, Rev. DÉpidémiologie Santé Publique, vol.62, pp.95-108, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915012

, Ovarian cancer, five-year stage-specific relative survival rates, J. Natl. Cancer Inst, vol.103, p.1287, 2004.

R. De-angelis, Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study, Lancet Oncol, vol.15, pp.23-34, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01915077

C. Sun, The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis, PLoS ONE, vol.9, p.95285, 2014.

B. Gronlund, C. Høgdall, H. H. Hansen, and S. A. Engelholm, Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma, Cancer, vol.94, pp.1961-1967, 2002.

, StatBite Ovarian Cancer, Five-Year Stage-Specific Relative Survival Rates, 2004.

, JNCI J. Natl. Cancer Inst, vol.103, pp.1287-1287, 2011.

R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis, J. Clin. Oncol, vol.20, pp.1248-1259, 2002.

A. Elattar, A. Bryant, B. A. Winter-roach, M. Hatem, and R. Naik, Optimal primary surgical treatment for advanced epithelial ovarian cancer, Cochrane Database Syst. Rev, 2011.

R. J. Kurman and I. Shih, Pathogenesis of Ovarian Cancer: Lessons From Morphology and Molecular Biology and Their Clinical Implications, Int. J. Gynecol. Pathol. PAP, 2008.

S. G. Silverberg, Histopathologic grading of ovarian carcinoma: a review and proposal, Int. J. Gynecol. Pathol. Off. J. Int. Soc. Gynecol. Pathol, vol.19, pp.7-15, 2000.

W. G. Mccluggage, Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis, Pathology (Phila.), vol.43, pp.420-432, 2011.

S. L. Rose, M. Kunnimalaiyaan, J. Drenzek, and N. Seiler, Notch 1 signaling is active in ovarian cancer, Gynecol. Oncol, vol.117, pp.130-133, 2010.

R. B. Ness and C. Cottreau, Possible role of ovarian epithelial inflammation in ovarian cancer, J. Natl. Cancer Inst, vol.91, pp.1459-1467, 1999.

M. F. Fathalla, Incessant ovulation--a factor in ovarian neoplasia?, Lancet Lond. Engl, vol.2, p.163, 1971.

N. N. Nik, R. Vang, I. Shih, and R. J. Kurman, Origin and Pathogenesis of Pelvic (Ovarian, Tubal, and Primary Peritoneal) Serous Carcinoma, Annu. Rev. Pathol. Mech. Dis, vol.9, pp.27-45, 2014.

D. S. Chi, What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?, Gynecol. Oncol, vol.103, pp.559-564, 2006.

D. S. Chi, Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm, Gynecol. Oncol, vol.114, pp.26-31, 2009.

I. Vergote, Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer, N. Engl. J. Med, vol.363, pp.943-953, 2010.

S. Kehoe, Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial, The Lancet, vol.386, pp.249-257, 2015.

. Harter and . Lion, Lymphadenectomy in ovarian neoplasms-A prospective randomized AGO study group led gynecologic cancer intergroup trial, Abstract JCO, vol.35, 2017.

N. Katsumata, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, The Lancet, vol.374, pp.1331-1338, 2009.

S. Pignata, Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, vol.15, pp.396-405, 2014.

R. A. Burger, Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer, N. Engl. J. Med, vol.365, pp.2473-2483, 2011.

T. J. Perren, A Phase 3 Trial of Bevacizumab in Ovarian Cancer, N. Engl. J. Med, vol.365, pp.2484-2496, 2011.

P. Therasse, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J. Natl. Cancer Inst, vol.92, pp.205-216, 2000.

M. K. Parmar, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet Lond. Engl, vol.361, pp.2099-2106, 2003.

S. Mahner, Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial, Eur. J. Cancer, vol.51, pp.352-358, 2015.

J. Pfisterer, Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J. Clin. Oncol, vol.24, pp.4699-4707, 2006.

J. M. Hall, Linkage of early-onset familial breast cancer to chromosome 17q21, Science, vol.250, pp.1684-1689, 1990.

A. R. Venkitaraman, Cancer suppression by the chromosome custodians, BRCA1 and BRCA2, Science, vol.343, pp.1470-1475, 2014.

A. G. Patel, J. N. Sarkaria, and S. H. Kaufmann, Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombinationdeficient cells, Proc. Natl. Acad. Sci. U. S. A, vol.108, pp.3406-3411, 2011.

B. A. Werness, Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations, Hum. Pathol, vol.31, pp.1420-1424, 2000.

N. Mavaddat, Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE, JNCI J. Natl. Cancer Inst, vol.105, pp.812-822, 2013.

S. Chen and G. Parmigiani, Meta-analysis of BRCA1 and BRCA2 penetrance, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol, vol.25, pp.1329-1333, 2007.

A. Antoniou, Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies, Am. J. Hum. Genet, vol.72, pp.1117-1130, 2003.

M. King, J. H. Marks, and J. B. Mandell, & New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2, Science, vol.302, pp.643-646, 2003.

J. M. Lancaster, C. B. Powell, L. Chen, and D. L. Richardson, Society of Gynecologic, vol.83

, Oncology statement on risk assessment for inherited gynecologic cancer predispositions, Gynecol. Oncol, vol.136, pp.3-7, 2015.

B. T. Hennessy, Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer, J. Clin. Oncol, vol.28, pp.3570-3576, 2010.

K. P. Pennington, Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas, Clin. Cancer Res, vol.20, pp.764-775, 2014.

H. Farmer, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-921, 2005.

A. Ashworth and . Synthetic, Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair, J. Clin. Oncol, vol.26, pp.3785-3790, 2008.

J. Z. Press, Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities, BMC Cancer, vol.8, 2008.
DOI : 10.1186/1471-2407-8-17

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-8-17

J. Ledermann, Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer, N. Engl. J. Med, vol.366, pp.1382-1392, 2012.

J. A. Ledermann, Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial, Lancet Oncol, vol.17, pp.1579-1589, 2016.

M. R. Mirza, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer, N. Engl. J. Med, vol.375, pp.2154-2164, 2016.

E. M. Swisher, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial, Lancet Oncol, vol.18, pp.75-87, 2017.

D. S. Tan and S. B. Kaye, Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?, Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Meet, vol.8, pp.114-121, 2015.

Q. Zhong, H. Peng, X. Zhao, L. Zhang, and W. Hwang, Effects of BRCA1-and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis, Clin. Cancer Res, vol.21, pp.211-220, 2015.

K. Xu, S. Yang, and Y. Zhao, Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis, Oncotarget, vol.8, 2017.

K. L. Bolton, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer, JAMA, vol.307, pp.382-390, 2012.

J. Boyd, Clinicopathologic features of BRCA-linked and sporadic ovarian cancer, JAMA, vol.283, pp.2260-2265, 2000.

A. Pauw and . De, Hereditary forms of ovarian cancer, Bull. Cancer, pp.453-462, 2012.

A. Melamed, Associations between residual disease and survival in epithelial ovarian cancer by histologic type, Gynecol. Oncol, vol.147, pp.250-256, 2017.
DOI : 10.1016/j.ygyno.2017.08.003

T. V. Gorodnova, High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation, Cancer Lett, vol.369, pp.363-367, 2015.

I. Vergote, Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer, Eur. J. Cancer, vol.47, pp.88-92, 2011.
DOI : 10.1016/s0959-8049(11)70152-6

V. Da-costa-miranda, Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness, Gynecol. Oncol, vol.132, pp.287-291, 2014.

E. Stoeckle, Progress in Survival Outcomes in Patients with Advanced Ovarian Cancer Treated by Neo-Adjuvant Platinum/Taxane-Based Chemotherapy and Late Interval Debulking Surgery, Ann. Surg. Oncol, vol.21, pp.629-636, 2014.

P. E. Colombo, Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer, Gynecol. Oncol, vol.135, pp.223-230, 2014.

, Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer (CHRONO) -NCT03579394, 2018.

P. M. Vencken, Chemosensitivity and outcome of BRCA1-and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients, Ann. Oncol, vol.22, pp.1346-1352, 2011.

. Femmes-porteuses-d'une-mutation, . De, and . Ou-brca2, Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque-E-Cancer, Avril 2017. 63. Zwakman, N. et al. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer, J. Gynecol. Oncol, vol.28, p.7, 2017.

E. Pujade-lauraine, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, Lancet Oncol, vol.18, pp.1274-1284, 2017.

D. Bell, Integrated genomic analyses of ovarian carcinoma, Nature, vol.474, pp.609-615, 2011.